Quality is critical to MMV’s mandate. We are dedicated to developing innovative medicines of the highest quality to address the unmet medical needs of vulnerable people at risk of malaria.
The best way to ensure quality is by meeting the rigorous guidelines of stringent regulatory authorities (SRAs),1 for example, those of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Swissmedic or the World Health Organization (WHO)’s prequalification programme.
SRA approval indicates a new medicine is safe and effective
SRA approval or opinion indicates a new medicine has met the highest levels of safety and effectiveness in the specific patient populations in which it was studied. These internationally recognized approvals also enable medicines to be procured and distributed by international funding bodies, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria.
MMV engages proactively with regulators early in the drug development process
The SRA assessment process of a new drug application (NDA) often takes about a year. To make the process as smooth as possible, MMV engages proactively with regulators early in the drug development process. Ahead of dossier submission, we ensure compliance with the clinical data requirements and incorporate regulatory guidance into the design of our protocols and trials. This decreases the risk of the dossier failing to meet the SRA’s standard and makes the process more efficient. In addition, this collaborative relationship with regulators, as well as with our development partners, allows MMV to leverage drug development experience and know-how towards the ultimate goal of benefiting patients.
Regular, real-time feedback translates to shorter drug development timelines
SRAs are keenly aware of the need for expedited development of drugs for neglected tropical diseases and malaria. In 2012, under its Food and Drug Administration Safety and Innovation Act,2 the FDA started the newest of four expedited review and development mechanisms for drug development:3 Breakthrough Therapy Designation.4 MMV/GlaxoSmithKline (GSK) received this designation in 2013 for tafenoquine. Consequently, we have had a number of consultations with the FDA during the phase IIb and III studies for tafenoquine and expect that the application will undergo an expedited review. The benefit of regular, real-time feedback translates to shorter drug development timelines which ultimately, for patients, means earlier access to lifesaving therapies.
Pyramax®, the first antimalarial to be granted a positive scientific opinion by the EMA
The EMA is also engaged in activities to support approval of medicines for neglected diseases. Since 2004, in cooperation with WHO, the EMA has been undertaking regulatory assessments and providing scientific opinion on products not intended for use in Europe through the Article 58 procedure. Pyramax® (pyronaridine-artesunate), developed by MMV and Shin Poong, was the first antimalarial to be granted a positive scientific opinion by the EMA under Article 58 in 2012.
Our goal: to develop high-quality antimalarials and ensure their timely access to patients
MMV also works closely with partners to ensure their medicines meet the criteria for inclusion in the WHO list of prequalified medicines. We consider WHO prequalification the seal of approval for medicines already listed on the WHO treatment guidelines.
MMV’s goal is crystal clear: to develop high-quality antimalarials and ensure their timely access to vulnerable populations. By interacting with regulatory bodies at each stage of development, and meeting their rigorous standards, we are working to realize this goal for malaria patients all around the world.
- A regulatory body which is: (a) a member of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) or (b) an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement currently including Australia, Iceland, Liechtenstein and Norway (http://apps.who.int/prequal/)
- The Food and Drug Administration Safety and Innovation Act, Public Law 112–144, 112th Congress (2012)
- The FDA’s Four Expedited Review Pathways for Drugs
- The FDA’s Breakthrough Therapy Designation
- WHO-TDR: World Health Organization Special Programme for Research and Training in Tropical Diseases.